Paul A Lapchak
Department of Neurology & Neurosurgery, Advanced Health Sciences Pavilion, Suite 8305,
127 S. San Vicente Blvd, Los Angeles, CA 90048
Tanzania
Research Article
Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke
Author(s): Paul A Lapchak and Paul D BoitanoPaul A Lapchak and Paul D Boitano
Current state-of-the-art acute ischemic stroke clinical trials are designed to study neuroprotectants when
administered following thrombolysis; tissue plasminogen activator (tPA) is administered to patients within 3-4.5
hours of an ischemic event. Thus, in order to develop a novel neuroprotectant and move it forward to a clinical trial, it
is important to assess the effects of the drug on tPA’s proteolytic activity in vitro, prior to extensive in vivo analysis.
In this study, we determined if CNB-001 [4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl-)-1-phenyl-1H-pyrazoyl-3-
yl)vinyl)-2-methoxy-phenol)], would affect, either enhance or inhibit tPA activity in vitro. In this tPA-inhibitor
(plasminogen activator inhibitor-1; PAI-1 and 2,7-Bis-(4-Amidinobenzylidene)-Cycloheptan-1-One Dihydrochloride;
tPA stop) controlled study, we used a chro.. View More»
